AIM
AIM ImmunoTech Inc.
Biotechnology
Market Cap$31M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AIM vs IMMP
Revenue, margins, valuation, and 5-year total return — side by side.
IMMP
Immutep Limited
Biotechnology
Market Cap$64M
5Y Perf.-89.5%
AIM vs IMMP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AIM | IMMP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $31M | $64M |
| Revenue (TTM) | $112K | $9M |
| Net Income (TTM) | $-16M | $-104M |
| Gross Margin | 18.8% | -8.4% |
| Operating Margin | -129.3% | -24.1% |
| Total Debt | $3M | $2M |
| Cash & Equiv. | $2M | $67M |
AIM vs IMMP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AIM
IMMP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | 100 | 0.2 | -99.8% |
| Immutep Limited (IMMP) | 100 | 10.5 | -89.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIM vs IMMP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMMP leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. AIM ImmunoTech Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
AIM
AIM ImmunoTech Inc.
The Income Pick
AIM is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.09
- Lower volatility, beta 1.09, current ratio 0.44x
- Beta 1.09, current ratio 0.44x
Best for: income & stability and sleep-well-at-night
IMMP
Immutep Limited
The Growth Play
IMMP carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 31.3%, EPS growth -16.7%, 3Y rev CAGR 209.4%
- -96.0% 10Y total return vs AIM's -100.0%
- 31.3% revenue growth vs AIM's -15.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMMP | 31.3% revenue growth vs AIM's -15.8% |
| Quality / Margins | IMMP | -11.7% margin vs AIM's -140.6% |
| Stability / Safety | AIM | Beta 1.09 vs IMMP's 1.44 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMMP | -77.6% vs AIM's -94.6% |
| Efficiency (ROA) | IMMP | -66.3% ROA vs AIM's -286.7%, ROIC -176.9% vs -5.5% |
AIM vs IMMP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
AIM vs IMMP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMMPLAGGINGAIM
AIMAIM ImmunoTech Inc.
0leads
IMMPImmutep Limited
3leads
6 Total Categories
CATEGORYLEADERvs AIMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMMP5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMMP6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
IMMP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMMP leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IMMP is the larger business by revenue, generating $9M annually — 79.3x AIM's $112,000. IMMP is the more profitable business, keeping -11.7% of every revenue dollar as net income compared to AIM's -140.6%. On growth, IMMP holds the edge at +9.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| RevenueTrailing 12 months | $112,000 | $9M |
| EBITDAEarnings before interest/tax | -$14M | -$210M |
| Net IncomeAfter-tax profit | -$16M | -$104M |
| Free Cash FlowCash after capex | -$13M | -$98M |
| Gross MarginGross profit ÷ Revenue | +18.8% | -8.4% |
| Operating MarginEBIT ÷ Revenue | -129.3% | -24.1% |
| Net MarginNet income ÷ Revenue | -140.6% | -11.7% |
| FCF MarginFCF ÷ Revenue | -119.0% | -11.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.7% | +9.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.5% | -50.0% |
IMMP leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — AIM and IMMP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| Market CapShares × price | $31M | $64M |
| Enterprise ValueMkt cap + debt − cash | $33M | $16M |
| Trailing P/EPrice ÷ TTM EPS | -1.81x | -1.42x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 184.53x | 17.41x |
| Price / BookPrice ÷ Book value/share | — | 0.60x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — AIM and IMMP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMMP leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
IMMP delivers a -72.5% return on equity — every $100 of shareholder capital generates $-73 in annual profit, vs $-4 for AIM. On the Piotroski fundamental quality scale (0–9), AIM scores 3/9 vs IMMP's 1/9, reflecting mixed financial health.
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | -72.5% |
| ROA (TTM)Return on assets | -2.9% | -66.3% |
| ROICReturn on invested capital | -5.5% | -176.9% |
| ROCEReturn on capital employed | -4.0% | -75.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | $1M | -$66M |
| Cash & Equiv.Liquid assets | $2M | $67M |
| Total DebtShort + long-term debt | $3M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -27.48x | -3646.75x |
IMMP leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IMMP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMMP five years ago would be worth $1,228 today (with dividends reinvested), compared to $29 for AIM. Over the past 12 months, IMMP leads with a -77.6% total return vs AIM's -94.6%. The 3-year compound annual growth rate (CAGR) favors IMMP at -35.3% vs AIM's -77.0% — a key indicator of consistent wealth creation.
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| YTD ReturnYear-to-date | -52.9% | -85.3% |
| 1-Year ReturnPast 12 months | -94.6% | -77.6% |
| 3-Year ReturnCumulative with dividends | -98.8% | -73.0% |
| 5-Year ReturnCumulative with dividends | -99.7% | -87.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -96.0% |
| CAGR (3Y)Annualised 3-year return | -77.0% | -35.3% |
IMMP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AIM and IMMP each lead in 1 of 2 comparable metrics.
Risk & Volatility
AIM is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than IMMP's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMMP currently trades 12.2% from its 52-week high vs AIM's 2.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 1.44x |
| 52-Week HighHighest price in past year | $19.15 | $3.53 |
| 52-Week LowLowest price in past year | $0.46 | $0.29 |
| % of 52W HighCurrent price vs 52-week peak | +2.9% | +12.2% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 32.3 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 18.9M |
Evenly matched — AIM and IMMP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | AIMAIM ImmunoTech In… | IMMPImmutep Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $4.25 |
| # AnalystsCovering analysts | — | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMMP leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallImmutep Limited (IMMP)Leads 3 of 6 categories
Loading custom metrics...
AIM vs IMMP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AIM or IMMP a better buy right now?
For growth investors, Immutep Limited (IMMP) is the stronger pick with 31.
3% revenue growth year-over-year, versus -15. 8% for AIM ImmunoTech Inc. (AIM). Analysts rate Immutep Limited (IMMP) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIM or IMMP?
Over the past 5 years, Immutep Limited (IMMP) delivered a total return of -87.
7%, compared to -99. 7% for AIM ImmunoTech Inc. (AIM). Over 10 years, the gap is even starker: IMMP returned -96. 0% versus AIM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIM or IMMP?
By beta (market sensitivity over 5 years), AIM ImmunoTech Inc.
(AIM) is the lower-risk stock at 1. 09β versus Immutep Limited's 1. 44β — meaning IMMP is approximately 32% more volatile than AIM relative to the S&P 500.
04Which is growing faster — AIM or IMMP?
By revenue growth (latest reported year), Immutep Limited (IMMP) is pulling ahead at 31.
3% versus -15. 8% for AIM ImmunoTech Inc. (AIM). On earnings-per-share growth, the picture is similar: AIM ImmunoTech Inc. grew EPS 48. 3% year-over-year, compared to -16. 7% for Immutep Limited. Over a 3-year CAGR, IMMP leads at 209. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AIM or IMMP?
Immutep Limited (IMMP) is the more profitable company, earning -1218.
0% net margin versus -101. 9% for AIM ImmunoTech Inc. — meaning it keeps -1218. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMMP leads at -25. 1% versus -116. 3% for AIM. At the gross margin level — before operating expenses — AIM leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AIM or IMMP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AIM or IMMP better for a retirement portfolio?
For long-horizon retirement investors, AIM ImmunoTech Inc.
(AIM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (AIM: -100. 0%, IMMP: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AIM and IMMP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AIM is a small-cap quality compounder stock; IMMP is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AIM: -25.7% · IMMP: 9.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.